During Wednesday’s current trade, ADURO BIOTECH, INC. (NASDAQ:ADRO)’s shares skyrocketed 102.41% to $34.41.
Aduro Biotech, Inc. (ADRO), declared the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of $17.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the initial public offering price, less the underwriting discount. Aduro’s common stock is predictable to start trading on The NASDAQ Global Select Market under the symbol “ADRO” on April 15, 2015. The offering is predictable to close on April 20, 2015, subject to customary closing conditions. Aduro estimates net proceeds from the offering will be about $107.7 million (assuming no exercise of the underwriters’ option to purchase additional shares of common stock), after deducting the underwriting discount and estimated offering expenses payable by Aduro. Aduro’s net proceeds from a concurrent private placement at a price of $17.00 per share are predictable to be $25.0 million.
BofA Merrill Lynch and Leerink Partners LLC are acting as joint book-running managers for the projected offering. William Blair and Canaccord Genuity are acting as co-managers.
Aduro Biotech, Inc. is a clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. Aduro’s lead platform is based on proprietary strains of live-attenuated, double-deleted (LADD) Listeria monocytogenes that induce a potent innate immune response and have been engineered to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity.
During an afternoon trade, XBIOTECH INC. (NASDAQ:XBIT)’s shares climbed 27.37% to $24.20, hitting its highest level today.
Yesterday, XBIOTECH declared the pricing of its initial public offering of 4,000,000 shares of its common stock at an initial public offering price of $19.00 per share for a total offering amount of $76,000,000, before the underwriting discount. The shares started trading on the NASDAQ Global Select Market today under the ticker symbol “XBIT.”
WR Hambrecht + Co is acting as the sole underwriter for the offering.
XBiotech is a leading developer of next-generation therapeutic antibodies. The Company is also innovating with manufacturing technology and clinical strategies to lessen capital requirements and reduce lead times for drug development.
Finally, DS Healthcare Group, Inc. (NASDAQ:DSKX), gained 35.63% Wednesday.
DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products has released financial results for the fourth quarter and full year for 2014.
Q4 2014 Highlights:
- Net revenues were $ 3,706,761 up 21% over Q4 2013
- Gross margins raise to 60.1% from 51.3% in Q4 2013
- Gross profits raise to $2,244,930 up 43% over Q4 2013
- Company reports net income of $227,662 contrast to a loss of $(944,860) in Q4 2013
- Adjusted EBITDAS, a non-GAAP financial measure resulted in a net gain of $1,007,847 from a loss of $(399,789) in Q4 2013.
Net revenues were $3,706,761 for the three months ended December 31, 2014, an raise of 21% over revenues of $3,058,626 in the year-earlier period. Revenue growth in the fourth quarter was driven by higher sales from the Company’s Mexican partner, raised revenue from international markets and a resumption of growth in our domestic sales.
Gross margin raised to 60.6% in the fourth quarter of 2014 from 51.3% in the same quarter of the preceding year. This notable raise was a result of several factors counting production efficiencies, planned cost cutting efforts, raised sales of higher margin products and lower returns due to improved product quality. Gross profits were up 43% to $2,244,930 in the fourth quarter of 2014, as contrast to $1,570,423 in the year-earlier period. Selling and marketing costs raised by 12% to $1,022,814 in the recent quarter from $913,951 in the same period last year. General and administrative costs reduced by 44.4% to $958,493, as contrast to $1,723,995 in the same period of 2013. DS Healthcare stated net loss narrowed by 125% to a net income of $227,662 in the fourth quarter of 2014 contrast to a net loss $(944,859) in the same period of 2013.
DS Healthcare Group, Inc., doing business as DS Laboratories, develops and markets hair care, skin care, and personal care products in North America and internationally. Its hair care products comprise Revita and Revita LT shampoos, and Revita.Cor conditioner for hair growth stimulation; Dandrene, an antifungal shampoo to treat itchy scalp and dandruff; and Spectral line of products comprising Spectral.DNC spray formula, Spectral.DNC-L lotion, and Spectral DNC-N to re-grow hair through various pathways, in addition to Spectral.RS, a topical treatment for men and women with advanced androgenic alopecia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
